A new anti-inflammatory compound has had some Phase 2 Clinical information published. COL-3 is a so called second generation IMPACS (Inhibitors of Multiple Proteases and Cytokines) compound. It is a tetracycline derivate, and is also designated as a Synthetic MMP (Matrix Metalloproteinsase) inhibitor.
Guy Webster, MD. PhD the lead investigator for these Phase 2 clinical trials of COL-3 says
“This is the first double-blinded, placebo-controlled clinical study evaluating COL-3’s therapeutic potential. The magnitude of the effect was greater than anticipated and the onset of action much faster, making COL-3 a promising candidate for development.”
COL-3 is being developed by Collagenex Pharmaceuticals who is also developing Oracea, another antibiotic variant targetted as a rosacea treatment.
According to Collagenex, research has shown that certain tetracyclines can be chemically modified to retain non-antibiotic properties that may make them effective in treating diseases involving inflammation and/or destruction of the body’s connective tissues.
COL-3 is also undergoing Phase I trials as an angiogenesis inhibitor.
Related Articles:
- Incyclinide (CollaGenex) gets NIH Funding
- Incyclinide phase 2 for acne
- low dose doxycycline hyclate (SDD)
- Subantimicrobial Dose Doxycycline for Acne and Rosacea
- Periostat (doxycycline) goes generic, get ready for Oracea
- Oracea approved by FDA for oral rosacea treatment
- incyclinide fails for rosacea, acne still possible
